# A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer

> **NCT03371017** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 595 (actual)

## Conditions studied

- Triple Negative Breast Neoplasms

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Placebo
- **DRUG:** Gemcitabine
- **DRUG:** Capecitabine
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT03371017
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-11
- **Primary completion:** 2024-10-23
- **Final completion:** 2024-10-23
- **Target enrollment:** 595 (ACTUAL)
- **Last updated:** 2025-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03371017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03371017, "A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03371017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*